Long-term GLP-1 maintenance is about consistent dosing, ongoing provider access, and predictable cost — not about microdosing gimmicks or promotional pricing that shifts once you're past the introductory period.
Luma Health's flat pricing ($197/month semaglutide, $297/month tirzepatide) doesn't change between your starting dose and your maintenance dose, which matters most for the months and years of maintenance that follow initial weight loss.
Most of the attention in GLP-1 marketing goes to the initial weight-loss phase, but maintenance — the months and years after you've reached your goal — is where a program's actual structure matters most. Here's what a good long-term maintenance approach looks like.
Why Maintenance Is a Different Phase
Once you've reached your target weight goal, the clinical objective shifts from active weight loss to sustaining that result long-term, which for most patients means continuing GLP-1 treatment at a stable maintenance dose rather than stopping. Research on stopping semaglutide shows meaningful weight regain within a year for most patients who fully discontinue treatment altogether — underscoring that obesity is treated as a chronic condition requiring ongoing management, similar to blood pressure or cholesterol medication, not a short course that ends once a goal is hit.
This distinction matters for how you evaluate any provider, including one you've used successfully during active weight loss up to this point. A provider well-suited to getting you started may not be the ideal fit for the years of ongoing maintenance that follow that initial phase, since the priorities shift from titration guidance and rapid problem-solving toward consistency, predictable cost, and low-friction long-term access.
It's worth periodically reassessing your provider relationship as you move deeper into maintenance, rather than simply assuming the choice you made at the start of treatment is automatically still the right one for you years later. Your needs, priorities, and even financial situation can shift meaningfully over that time, and the provider that fit you well at the beginning may not be the one that fits you best for the long haul ahead.
What Should (and Shouldn't) Change at Maintenance
Your dose may be adjusted downward once you're at a genuinely stable weight, depending on how you're tolerating your current dose and your provider's clinical judgment — this is a legitimate, provider-guided decision, not something to self-manage. What shouldn't change is the fundamentals: continued access to your provider for questions, consistent medication supply, and monitoring for any long-term considerations relevant to your health profile.
It's worth having an explicit, direct conversation with your provider about what maintenance will look like specifically for you going forward — how often you'll check in, what triggers a dose reassessment, and what ongoing monitoring, if any, is planned. Providers vary considerably in how proactively and thoughtfully they manage this transition, and knowing what to expect helps you evaluate whether your current provider is handling it well for your specific situation.
Some providers explicitly outline a clear maintenance protocol as part of their onboarding process, while others handle it more informally on a case-by-case basis as individual patients reach their goals. Neither approach is inherently wrong, but a provider with a clear, explicitly articulated maintenance plan tends to give patients considerably more confidence about what to expect long-term, rather than leaving that transition to be figured out reactively once a patient's active weight-loss phase concludes.
Some programs advertise low introductory pricing tied to starting doses, with costs rising as you reach the higher maintenance doses most patients settle into long-term. If a program's advertised price is meaningfully lower than what you'll actually pay once you're at maintenance, that's genuinely worth factoring into your real long-term cost comparison — not just your very first month's bill alone.
How Fridays' Comprehensive Model Applies to Maintenance
Fridays' bundled coaching and group-support structure, valuable for many patients during active weight loss, is worth reassessing specifically for the maintenance phase. Once you've reached a stable weight and dose, the ongoing value of weekly group coaching and dietitian sessions may look considerably different than it did during the more intensive early stages of treatment itself, when frequent guidance and troubleshooting were more clearly useful and necessary.
This isn't a criticism of Fridays' comprehensive model at all — some patients continue to value structured accountability indefinitely, and there's absolutely nothing wrong with that preference. It's simply worth reassessing periodically whether the bundled services are still delivering proportional value at this stage, rather than assuming your initial reasons for choosing a comprehensive program still apply unchanged years into maintenance.
A useful, practical way to test this genuinely: ask yourself honestly and specifically how many of the past several coaching or group sessions you've genuinely engaged with versus attended passively or skipped entirely. If engagement has dropped off naturally as you've stabilized over time, that's a meaningful signal genuinely worth acting on decisively, rather than continuing to pay for a service you're no longer actively using in the way it was originally designed to be used.
A Note on Microdosing for Maintenance
Some programs market "microdosing" — using lower-than-standard doses — as a maintenance strategy, sometimes framed as reducing side effects or cost. This isn't a standard, extensively studied dosing approach backed by the same rigorous clinical trial data as FDA-labeled dosing schedules currently in use, and any dose below the studied range should be a provider's individualized clinical decision based on your specific response, not a default marketing strategy applied broadly.
If a provider is recommending microdosing primarily as a way to reduce your overall monthly cost rather than based on your individual clinical response and demonstrated tolerance, it's worth asking directly what specific evidence supports that particular dose for maintaining your results long-term, rather than simply accepting a lower dose purely because it's positioned as a cost-saving feature of the program.
This isn't to say every below-label dose is inherently inappropriate for every patient — some patients genuinely do maintain their results well on a considerably lower dose than their peak titration level, and a thoughtful provider may recommend this based on your individual response and tolerance over time. The distinction that matters most is between an individualized clinical decision made collaboratively with your provider and a blanket marketing strategy applied uniformly to every single patient regardless of their specific situation.
What Actually Matters for Long-Term Maintenance
Over months and years of maintenance, the things that matter most are: predictable pricing that doesn't surprise you once you've settled into a stable dose, consistent access to your provider without having to re-justify your treatment repeatedly, and a straightforward refill process that doesn't require renegotiating your program terms every few months.
A flat-rate model, like Luma Health's $197/month semaglutide or $297/month tirzepatide option, is specifically and genuinely well-suited to this phase, since your cost doesn't shift as your dose stabilizes at whatever level works best for you long-term. This predictability matters considerably more the longer you're actually on maintenance, since even a small monthly cost difference compounds meaningfully over years of ongoing treatment and continued use.
Beyond pricing, it's also worth considering how easy the actual refill process is on a month-to-month basis once you're settled into a stable routine. A provider that requires a fresh evaluation, additional paperwork, or renewed justification for treatment at every single refill creates unnecessary friction for a patient who's simply continuing an established, working treatment plan rather than starting something entirely new each time.
Switching Providers Once You're Already at Maintenance
If you decide a different provider would serve your maintenance phase better than your current one, this transition is generally straightforward from a medical standpoint, since you're already at a stable dose rather than mid-titration. Share your current dose and treatment history with your new provider so they can continue that same established dose without any unnecessary disruption to your existing, working treatment routine that's been serving you well.
This kind of switch, made specifically because your priorities have genuinely shifted from active weight loss to long-term maintenance, is a common and reasonable reason to change providers — it doesn't reflect dissatisfaction with your original choice, simply a recognition that different phases of treatment can call for different provider strengths, service models, and cost structures over time.
What to Prioritize for Maintenance
Before committing to any specific provider for the long term, it's worth stepping back and confirming that their pricing, access model, and refill process will genuinely serve you well for years of ongoing maintenance, not just the more intensive early months of active weight loss. A provider that excelled during your initial titration period isn't automatically the best fit for years of stable, ongoing treatment, and it's worth periodically confirming that assumption rather than simply staying with your original choice by default.
- What you'll actually pay at your expected maintenance dose, not just the starter price
- Whether ongoing provider access is included or requires additional fees
- How refills and dose adjustments work once you're stable
- Flat pricing that doesn't rise as your dose stabilizes higher
- Ongoing provider check-ins, not a one-time prescription
- Clear guidance on refill timing to avoid a treatment gap
Built for the long run,
not just month one
Compounded semaglutide at $197/month or tirzepatide at $297/month — the same price at your starting dose and your maintenance dose.
Get Started → Or start your free health assessmentFrequently Asked Questions
Not necessarily forever, but most patients continue at a maintenance dose, since stopping is associated with meaningful weight regain for most people within a year. This is a decision to make with your provider based on your individual situation.
Possibly, depending on your tolerance and your provider's clinical judgment. Some patients transition to a lower maintenance dose; others continue at their existing dose. This should be a provider-guided decision.
Using doses below the studied clinical range isn't backed by the same extensive trial data as FDA-labeled dosing, and should be an individualized provider decision based on your specific response, not a default strategy.
Some providers price by dose tier, meaning cost rises as you move from a starting dose to a higher maintenance dose. Confirm whether a program's advertised price reflects your expected long-term dose, not just the starting price.
Predictable pricing, ongoing provider access for questions and adjustments, and a straightforward refill process — without requiring you to renegotiate terms repeatedly.
No. Luma Health's $197/month semaglutide and $297/month tirzepatide are flat regardless of dose, including maintenance doses.
It depends on whether you're still actively engaging with the coaching and group sessions. Some patients value ongoing accountability indefinitely; others find the value proposition shifts once they've reached a stable weight.
Ask how often you'll check in, what would trigger a dose reassessment, and what ongoing monitoring is planned. Providers vary considerably in how proactively they manage this transition.
References
- Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. PubMed 35441470
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. PubMed 35658024
- U.S. Food and Drug Administration. Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide). FDA.gov. 2025. FDA Drug Approvals Database